Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Average Price Target from Analysts
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average […]
More Stories
Versarien (LON:VRS) Shares Up 3.4% – Here’s Why
Versarien plc (LON:VRS – Get Free Report)’s share price shot up 3.4% on Monday . The company traded as high...
Ennis (NYSE:EBF) Releases Earnings Results, Meets Estimates
Ennis (NYSE:EBF – Get Free Report) announced its quarterly earnings results on Monday. The industrial products company reported $0.39 EPS...
Head-To-Head Survey: Shopify (NYSE:SHOP) versus Ceridian HCM (NYSE:CDAY)
Shopify (NYSE:SHOP – Get Free Report) and Ceridian HCM (NYSE:CDAY – Get Free Report) are both large-cap computer and technology...
Botswana Diamonds (LON:BOD) Stock Price Up 36.9% – Time to Buy?
Botswana Diamonds plc (LON:BOD – Get Free Report) shares were up 36.9% on Monday . The stock traded as high...
Thermo Fisher Scientific (NYSE:TMO) Earns Sector Perform Rating from Analysts at Scotiabank
Equities research analysts at Scotiabank assumed coverage on shares of Thermo Fisher Scientific (NYSE:TMO – Get Free Report) in a...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given “Market Outperform” Rating at JMP Securities
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report)‘s stock had its “market outperform” rating restated by stock analysts at JMP Securities...